NEWTOWN, Pa.--(BUSINESS WIRE)--Onconova Therapeutics, Inc. announced today the publication of positive results from a first-in-human Phase I clinical trial of its lead anticancer drug, ON 01910.Na, in advanced refractory solid tumors. The publication will be online today in the Journal of Clinical Oncology and will appear in a future print edition of the journal. A first-in-class targeted therapy, ON 01910.Na is a potent and selective mitotic pathway modulator that selectively disrupts the cell cycle transition in cancer cells at the G2-M stage, leading to their self-destruction.
